Your browser doesn't support javascript.
loading
The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.
Stabile, Armando; Orczyk, Clement; Giganti, Francesco; Moschini, Marco; Allen, Clare; Punwani, Shonit; Cathala, Nathalie; Ahmed, Hashim U; Cathelineau, Xavier; Montorsi, Francesco; Emberton, Mark; Briganti, Alberto; Sanchez-Salas, Rafael; Moore, Caroline M.
Afiliação
  • Stabile A; Department of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Department of Urology, Institut Mutualiste Montsouris
  • Orczyk C; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
  • Giganti F; Division of Surgery and Interventional Science, University College London, London, UK; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Moschini M; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France; Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland.
  • Allen C; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Punwani S; Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Cathala N; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
  • Ahmed HU; Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Cathelineau X; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
  • Montorsi F; Department of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Emberton M; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
  • Briganti A; Department of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Sanchez-Salas R; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
  • Moore CM; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; Division of Surgery and Interventional Science, University College London, London, UK.
Eur Urol ; 78(2): 155-160, 2020 08.
Article em En | MEDLINE | ID: mdl-32444261
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico / Ablação por Ultrassom Focalizado de Alta Intensidade Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico / Ablação por Ultrassom Focalizado de Alta Intensidade Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article